8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Apr 9, 2026·SEC
Material company update
Feb 24, 2026·SEC
Orthofix Medical Inc.(OFIX)Earnings, Financials & Key Ratios
OFIX•NASDAQ
Price updated Jun 19, 2026
AboutOrthofix Medical Inc. operates as a medical device and biologics company in the United States, Italy, Germany, France, the United Kingdom, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion, as well as used as a therapeutic treatment for non-spinal and appendicular fractures. This segment also designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and a portfolio of products and tissue forms that allow physicians to treat a range of spinal and orthopedic conditions, as well as markets regenerative non-tissue biologic solutions derived from synthetic materials. The Global Orthopedics segment designs, develops, and markets orthopedic products that are used in fracture repair, deformity correction, and bone reconstruction procedures. The company markets and distributes its products through direct sales representatives; independent distributors; and employed and independent sales representatives to physicians, hospitals, ambulatory surgery centers, integrated health delivery systems, and other purchasing organizations. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in July 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.Show more
- Revenue$822M+2.9%
- EBITDA-$17M+28.7%
- Net Income-$92M+26.8%
- EPS (Diluted)-2.28+30.9%
- Gross Margin67.09%-1.7%
- EBITDA Margin-2.13%+30.7%
- Operating Margin-8.33%+21.3%
- Net Margin-11.21%+28.9%
- ROE-19.34%+15.4%
OFIX Key Insights
Orthofix Medical Inc. (OFIX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 15.1%
- ✓Trading at only 0.8x book value
✗Weaknesses
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 14 (bottom 14%)
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when OFIX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
OFIX Price & Volume
Orthofix Medical Inc. (OFIX) stock price & volume — 10-year historical chart
Loading chart...
OFIX Growth Metrics
Orthofix Medical Inc. (OFIX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years7.57%
5 Years15.13%
3 Years21.3%
TTM2.59%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM58.06%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM59.2%
Return on Capital
10 Years-2.88%
5 Years-10.26%
3 Years-15.22%
Last Year-9.75%
OFIX Recent Earnings
Orthofix Medical Inc. (OFIX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$0.52+23.5%
$0.68
Rev
$197M+0.2%
$196M
Q1 2026
Feb 24, 2026Metric
Actual
Est
EPS
$0.06+70.8%
$0.19
Rev
$220M+0.6%
$219M
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$0.20+66.7%
$0.12
Rev
$206M+2.8%
$200M
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$0.13+225.0%
$0.04
Rev
$203M+1.0%
$201M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.52vs $0.68+23.5% | $197Mvs $196M+0.2% |
| Q1 2026 | Feb 24, 2026 | $0.06vs $0.19+70.8% | $220Mvs $219M+0.6% |
| Q4 2025 | Nov 4, 2025 | $0.20vs $0.12+66.7% | $206Mvs $200M+2.8% |
| Q3 2025 | Aug 5, 2025 | $0.13vs $0.04+225.0% | $203Mvs $201M+1.0% |
Based on last 12 quarters of dataView full earnings history →
OFIX Peer Comparison
Orthofix Medical Inc. (OFIX) competitors in Orthopedics, spine, and sports medicine — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 ATEC | 1.33B | 8.81 | -9.18 | 24.95% | -21.07% | -443.09% | 17.21 | |
 XTNT | 61.8M | 0.44 | 14.69 | 14.21% | 1.5% | 3.68% | 0.56 | |
 NVAX | 1.5B | 9.13 | 3.59 | 64.69% | -14.73% | |||
 GMED | 10.69B | 79.23 | 20.21 | 16.65% | 18.92% | 13.04% | 0.03 | |
 SYK | 117.88B | 307.80 | 36.64 | 11.16% | 12.92% | 15.04% | 0.66 | |
 ZBH | 17.22B | 87.97 | 24.78 | 7.2% | 9.05% | 5.77% | 0.59 | |
 HOLX | 16.97B | 76.01 | 30.53 | 1.74% | 13.18% | 11.01% | 0.52 |
Compare OFIX vs Peers
Orthofix Medical Inc. (OFIX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
OFIX Income Statement
Orthofix Medical Inc. (OFIX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 433.82M | 453.04M | 459.95M | 406.56M | 464.48M | 460.71M | 746.64M | 799.49M | 822.31M | 825.37M |
Revenue Growth % | 5.87% | 4.43% | 1.53% | -11.61% | 14.25% | -0.81% | 62.06% | 7.08% | 2.85% | 2.59% |
Cost of Goods Sold | 93.04M | 96.63M | 100.61M | 101.89M | 114.91M | 123.54M | 260.37M | 253.61M | 270.61M | 255.74M |
COGS % of Revenue | 21.45% | 21.33% | 21.87% | 25.06% | 24.74% | 26.82% | 34.87% | 31.72% | 32.91% | - |
Gross Profit | 340.79M▲ 0% | 356.41M▲ 4.6% | 359.35M▲ 0.8% | 304.67M▼ 15.2% | 349.56M▲ 14.7% | 337.17M▼ 3.5% | 486.27M▲ 44.2% | 545.88M▲ 12.3% | 551.71M▲ 1.1% | 569.63M▲ 0% |
Gross Margin % | 78.55% | 78.67% | 78.13% | 74.94% | 75.26% | 73.18% | 65.13% | 68.28% | 67.09% | 69.02% |
Gross Profit Growth % | 5.86% | 4.59% | 0.82% | -15.22% | 14.73% | -3.55% | 44.22% | 12.26% | 1.07% | - |
Operating Expenses | 302.46M | 323.25M | 378.13M | 310.94M | 357.88M | 350.44M | 625.38M | 630.5M | 620.18M | 599.91M |
OpEx % of Revenue | 69.72% | 71.35% | 82.21% | 76.48% | 77.05% | 76.06% | 83.76% | 78.86% | 75.42% | - |
Selling, General & Admin | 272.76M | 290.03M | 309.28M | 272.38M | 290.67M | 308.78M | 530.39M | 532.52M | 456.39M | 555.96M |
SG&A % of Revenue | 62.87% | 64.02% | 67.24% | 67% | 62.58% | 67.02% | 71.04% | 66.61% | 55.5% | - |
Research & Development | 29.7M | 33.22M | 34.64M | 39.06M | 49.62M | 49.06M | 80.23M | 73.64M | 57.11M | 61.4M |
R&D % of Revenue | 6.85% | 7.33% | 7.53% | 9.61% | 10.68% | 10.65% | 10.75% | 9.21% | 6.95% | - |
Other Operating Expenses | 0 | 0 | 34.21M | -499K | 17.59M | -7.4M | 14.76M | 24.34M | 106.68M | 1000K |
Operating Income | 40.81M▲ 0% | 30.09M▼ 26.3% | -18.78M▼ 162.4% | -6.27M▲ 66.6% | -8.31M▼ 32.7% | -13.27M▼ 59.6% | -139.11M▼ 948.5% | -84.62M▲ 39.2% | -68.47M▲ 19.1% | -33.28M▲ 0% |
Operating Margin % | 9.41% | 6.64% | -4.08% | -1.54% | -1.79% | -2.88% | -18.63% | -10.58% | -8.33% | -4.03% |
Operating Income Growth % | 93.72% | -26.26% | -162.42% | 66.64% | -32.7% | -59.57% | -948.46% | 39.17% | 19.08% | - |
EBITDA | 60.94M | 48.75M | 9.69M | 28.01M | 24.78M | 18.81M | -78.55M | -24.56M | -17.5M | 102.09M |
EBITDA Margin % | 14.05% | 10.76% | 2.11% | 6.89% | 5.34% | 4.08% | -10.52% | -3.07% | -2.13% | 12.37% |
EBITDA Growth % | 45.4% | -19.99% | -80.12% | 188.97% | -11.53% | -24.11% | -517.66% | 68.74% | 28.74% | 1258.53% |
D&A (Non-Cash Add-back) | 20.12M | 18.66M | 28.48M | 34.28M | 33.1M | 32.08M | 60.56M | 60.06M | 50.97M | 135.37M |
EBIT | 40.81M | 22.89M | -26.93M | 2.12M | -11.66M | -16.42M | -140.05M | -94.24M | -73.32M | -36.38M |
Net Interest Income | -416K | -828K | -122K | -2.48M | -1.84M | -1.29M | -8.63M | -29.63M | -17.49M | -18.65M |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 416K | 828K | 122K | 2.48M | 1.84M | 1.29M | 8.63M | 29.63M | 17.49M | 7.32M |
Other Income/Expense | -4.42M | -7.21M | -8.27M | 5.9M | -5.18M | -4.44M | -9.57M | -39.26M | -22.34M | -26.23M |
Pretax Income | 36.39M▲ 0% | 22.89M▼ 37.1% | -27.05M▼ 218.2% | -368K▲ 98.6% | -13.49M▼ 3567.1% | -17.71M▼ 31.2% | -148.68M▼ 739.7% | -123.88M▲ 16.7% | -90.81M▲ 26.7% | -59.51M▲ 0% |
Pretax Margin % | 8.39% | 5.05% | -5.88% | -0.09% | -2.91% | -3.84% | -19.91% | -15.49% | -11.04% | -7.21% |
Income Tax | 29.1M | 9.07M | 1.41M | -2.88M | 24.88M | 2.04M | 2.72M | 2.12M | 1.38M | 347K |
Effective Tax Rate % | 79.96% | 39.65% | -5.22% | 783.97% | -184.39% | -11.54% | -1.83% | -1.71% | -1.52% | -0.58% |
Net Income | 6.22M▲ 0% | 13.81M▲ 121.9% | -28.46M▼ 306.1% | 2.52M▲ 108.8% | -38.38M▼ 1624.8% | -19.75M▲ 48.5% | -151.4M▼ 666.6% | -126M▲ 16.8% | -92.19M▲ 26.8% | -60.01M▲ 0% |
Net Margin % | 1.43% | 3.05% | -6.19% | 0.62% | -8.26% | -4.29% | -20.28% | -15.76% | -11.21% | -7.27% |
Net Income Growth % | 103.63% | 121.93% | -306.08% | 108.84% | -1624.79% | 48.54% | -666.6% | 16.78% | 26.83% | 58.06% |
Net Income (Continuing) | 7.29M | 13.81M | -28.46M | 2.52M | -38.38M | -19.75M | -151.4M | -126M | -92.19M | -60.01M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 0.34▲ 0% | 0.73▲ 114.7% | -1.51▼ 306.8% | 0.13▲ 108.6% | -1.95▼ 1600.0% | -0.98▲ 49.7% | -4.12▼ 320.4% | -3.30▲ 19.9% | -2.28▲ 30.9% | -1.48▲ 0% |
EPS Growth % | 100% | 114.71% | -306.85% | 108.61% | -1600% | 49.74% | -320.41% | 19.9% | 30.91% | 59.2% |
EPS (Basic) | 0.34 | 0.75 | -1.51 | 0.13 | -1.95 | -0.98 | -4.12 | -3.30 | -2.28 | - |
Diluted Shares Outstanding | 18.5M | 18.91M | 18.9M | 19.39M | 19.69M | 20.1M | 36.73M | 38.13M | 39.88M | 40.45M |
Basic Shares Outstanding | 18.12M | 18.49M | 18.9M | 19.27M | 19.69M | 20.1M | 36.73M | 38.13M | 39.88M | 40.45M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
OFIX Balance Sheet
Orthofix Medical Inc. (OFIX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 251.8M | 244.64M | 260.55M | 270.38M | 269.52M | 255.99M | 420.44M | 433.29M | 416.85M | 461.52M |
Cash & Short-Term Investments | 81.16M | 69.62M | 69.72M | 96.29M | 87.85M | 50.7M | 33.11M | 83.24M | 82.03M | 120.28M |
Cash Only | 81.16M | 69.62M | 69.72M | 96.29M | 87.85M | 50.7M | 33.11M | 83.24M | 82.03M | 120.28M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 63.44M | 77.75M | 86.81M | 72.42M | 78.56M | 82.86M | 128.1M | 134.71M | 135.75M | 137.78M |
Days Sales Outstanding | 53.37 | 62.64 | 68.88 | 65.02 | 61.73 | 65.64 | 62.62 | 61.5 | 60.25 | 59.02 |
Inventory | 81.33M | 76.85M | 82.4M | 84.64M | 82.97M | 100.15M | 222.17M | 189.45M | 34.17M | 177.82M |
Days Inventory Outstanding | 319.07 | 290.28 | 298.93 | 303.19 | 263.55 | 295.88 | 311.45 | 272.67 | 46.09 | 248.75 |
Other Current Assets | 0 | 2.57M | 684K | 530K | 0 | 22.28M | 37.07M | 25.88M | 164.91M | 25.65M |
Total Non-Current Assets | 153.55M | 222M | 235.07M | 255.48M | 207.1M | 202.64M | 504.87M | 460.01M | 433.8M | 425.08M |
Property, Plant & Equipment | 45.14M | 42.84M | 62.73M | 63.61M | 59.25M | 58.23M | 159.06M | 139.8M | -11.09M | 125.33M |
Fixed Asset Turnover | 9.61x | 10.58x | 7.33x | 6.39x | 7.84x | 7.91x | 4.69x | 5.72x | - | 5.87x |
Goodwill | 53.56M | 72.4M | 71.18M | 84.02M | 71.32M | 71.32M | 194.93M | 194.93M | 194.93M | 194.93M |
Intangible Assets | 10.46M | 51.9M | 54.14M | 60.52M | 52.67M | 47.39M | 117.49M | 98.8M | 72.77M | 69.34M |
Long-Term Investments | 0 | 219K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 21.07M | 21.42M | 11.91M | 22.29M | 22.09M | 25.7M | 33.39M | 26.47M | -77.44M | 35.48M |
Total Assets | 405.35M▲ 0% | 466.64M▲ 15.1% | 495.62M▲ 6.2% | 525.86M▲ 6.1% | 476.62M▼ 9.4% | 458.63M▼ 3.8% | 925.32M▲ 101.8% | 893.29M▼ 3.5% | 850.65M▼ 4.8% | 886.6M▲ 0% |
Asset Turnover | 1.07x | 0.97x | 0.93x | 0.77x | 0.97x | 1.00x | 0.81x | 0.89x | 0.97x | 0.97x |
Asset Growth % | 8.94% | 15.12% | 6.21% | 6.1% | -9.36% | -3.78% | 101.76% | -3.46% | -4.77% | -6.21% |
Total Current Liabilities | 79.41M | 85.91M | 84.88M | 103.9M | 105.83M | 83.62M | 165.22M | 168.63M | 170.48M | 161.03M |
Accounts Payable | 18.11M | 17.99M | 19.89M | 23.12M | 26.46M | 27.6M | 58.36M | 48.8M | 58.39M | 54.69M |
Days Payables Outstanding | 71.05 | 67.95 | 72.15 | 82.82 | 84.04 | 81.54 | 81.81 | 70.24 | 78.76 | 74.44 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 1.25M | 0 | 3.98M | 115K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 9.63M | 46.31M | 48.79M | 24.73M | 21.99M | 0 | 1M | 7.1M | 81.08M | 106.23M |
Current Ratio | 3.17x | 2.85x | 3.07x | 2.60x | 2.55x | 3.06x | 2.54x | 2.57x | 2.45x | 2.87x |
Quick Ratio | 2.15x | 1.95x | 2.10x | 1.79x | 1.76x | 1.86x | 1.20x | 1.45x | 2.24x | 1.76x |
Cash Conversion Cycle | 301.39 | 284.97 | 295.67 | 285.39 | 241.24 | 279.99 | 292.26 | 263.93 | 27.58 | 233.34 |
Total Non-Current Liabilities | 29.34M | 45.34M | 83.11M | 65.1M | 33.86M | 38.15M | 161.36M | 221.54M | 230.13M | 290.38M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 93.11M | 157.01M | 182.8M | 234.27M |
Capital Lease Obligations | 0 | 0 | 20.65M | 22.34M | 19.89M | 19.24M | 18.53M | 17.84M | 42.47M | 129.61M |
Deferred Tax Liabilities | 0 | 0 | 11.99M | 0 | 0 | 0 | 0 | 0 | 6.08M | 6.08M |
Other Non-Current Liabilities | 29.34M | 45.34M | 62.46M | 42.76M | 13.97M | 18.91M | 49.72M | 46.69M | -1.23M | 56.11M |
Total Liabilities | 108.75M | 131.24M | 167.99M | 169M | 139.69M | 121.77M | 326.58M | 390.17M | 400.61M | 451.42M |
Total Debt | 0 | 0 | 22.85M | 24.94M | 24.31M | 21.53M | 117.07M | 179.63M | 229.26M | 234.39M |
Net Debt | -81.16M | -69.62M | -46.87M | -71.35M | -63.53M | -29.17M | 83.97M | 96.39M | 147.24M | 114.11M |
Debt / Equity | - | - | 0.07x | 0.07x | 0.07x | 0.06x | 0.20x | 0.36x | 0.51x | 0.54x |
Debt / EBITDA | - | - | 2.36x | 0.89x | 0.98x | 1.14x | - | - | - | 2.30x |
Net Debt / EBITDA | -1.33x | -1.43x | -4.84x | -2.55x | -2.56x | -1.55x | - | - | - | 1.12x |
Interest Coverage | 98.10x | 27.64x | -220.71x | 0.85x | -6.35x | -12.75x | -16.23x | -3.18x | -4.19x | -4.97x |
Total Equity | 296.61M▲ 0% | 335.4M▲ 13.1% | 327.63M▼ 2.3% | 356.86M▲ 8.9% | 336.93M▼ 5.6% | 336.86M▼ 0.0% | 598.73M▲ 77.7% | 503.12M▼ 16.0% | 450.04M▼ 10.6% | 435.19M▲ 0% |
Equity Growth % | 12.57% | 13.08% | -2.32% | 8.92% | -5.58% | -0.02% | 77.74% | -15.97% | -10.55% | -47.51% |
Book Value per Share | 16.03 | 17.73 | 17.33 | 18.40 | 17.11 | 16.76 | 16.30 | 13.19 | 11.28 | 10.76 |
Total Shareholders' Equity | 296.61M | 335.4M | 327.63M | 356.86M | 336.93M | 336.86M | 598.73M | 503.12M | 450.04M | 435.19M |
Common Stock | 1.83M | 1.86M | 1.9M | 1.94M | 1.98M | 2.02M | 3.72M | 3.85M | 3.98M | 4.04M |
Retained Earnings | 70.4M | 87.08M | 57.75M | 59.38M | 21M | 1.25M | -150.14M | -276.14M | -368.33M | -389.24M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 3.79M | 3.3M | -3.04M | 3.25M | 0 | -1.38M | -1.29M | -4.3M | 618K | 142K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
OFIX Cash Flow Statement
Orthofix Medical Inc. (OFIX) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 53.34M | 49.92M | 32.03M | 74.27M | 18.48M | -11.54M | -45.75M | 25.79M | 33.35M | 34.91M |
Operating CF Margin % | 12.3% | 11.02% | 6.96% | 18.27% | 3.98% | -2.5% | -6.13% | 3.23% | 4.06% | - |
Operating CF Growth % | 19.31% | -6.42% | -35.83% | 131.86% | -75.13% | -162.45% | -296.54% | 156.37% | 29.3% | 60.08% |
Net Income | 6.22M | 13.81M | -28.46M | 2.52M | -38.38M | -19.75M | -151.4M | -126M | 0 | -60.01M |
Depreciation & Amortization | 20.12M | 18.66M | 24.7M | 34.28M | 33.09M | 32.08M | 60.6M | 75.96M | 0 | 136.43M |
Stock-Based Compensation | 12.56M | 18.93M | 21.54M | 16.21M | 15.43M | 18.44M | 35.71M | 32.45M | 0 | 42.3M |
Deferred Taxes | 21.29M | -2.66M | 1.39M | 10.79M | 24.48M | 314K | 579K | 1.88M | 0 | 117K |
Other Non-Cash Items | 10.33M | 8.18M | 42.24M | -9.21M | 1.95M | -13.39M | 62.72M | 60.74M | 54.84M | 117.54M |
Working Capital Changes | -17.18M | -7M | -29.38M | 19.7M | -18.1M | -29.23M | -53.96M | -19.25M | -21.5M | -83.42M |
Change in Receivables | -6.56M | -3.71M | -11.04M | 13.28M | -7.05M | -6.74M | -10.41M | -9.53M | -1.58M | 5.26M |
Change in Inventory | -15.64M | 9.7M | -5.71M | -873K | 619K | -18.13M | -58.05M | -5.55M | -10.75M | -24.2M |
Change in Payables | 2.32M | -170K | 2.14M | 2.53M | 4.25M | 2.28M | 8.64M | -5.57M | 2.6M | -22.64M |
Cash from Investing | -16.47M | -61M | -22.92M | -52.33M | -23.01M | -24.53M | -33.13M | -27.58M | -34.6M | -38.38M |
Capital Expenditures | -16.95M | -15.26M | -20.52M | -17.09M | -19.59M | -23.16M | -62.05M | -34.88M | 0 | -48.26M |
CapEx % of Revenue | 3.91% | 3.37% | 4.46% | 4.2% | 4.22% | 5.03% | 8.31% | 4.36% | 4.21% | 5.85% |
Acquisitions | 0 | -44.29M | 0 | -18M | 0 | -1.5M | 29.42M | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 474K | -1.45M | -2.4M | -24.33M | -1.25M | 0 | -500K | -100K | -34.6M | 9.88M |
Cash from Financing | 3.54M | 2.99M | -10.69M | 3.25M | -3.62M | -78K | 65.32M | 50.71M | -786K | 63.96M |
Debt Issued (Net) | 0 | 0 | -365K | -323K | -537K | -2.59M | 67.95M | 54.39M | -762K | 63.42M |
Equity Issued (Net) | 7.78M | 7.1M | 11.55M | 7.6M | 8.82M | 4.34M | 5.13M | 6.26M | 5.93M | 5.88M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -9K |
Other Financing | -4.25M | -4.11M | -21.87M | -4.03M | -11.91M | -1.82M | -7.75M | -9.94M | -5.95M | -5.34M |
Net Change in Cash | 41.59M▲ 0% | -8.97M▼ 121.6% | -1.79M▲ 80.1% | 26.42M▲ 1579.2% | -8.97M▼ 134.0% | -37.15M▼ 313.9% | -12.94M▲ 65.2% | 47.98M▲ 470.7% | -623K▼ 101.3% | 60.42M▲ 0% |
Free Cash Flow | 36.39M▲ 0% | 34.66M▼ 4.8% | 11.51M▼ 66.8% | 57.18M▲ 396.8% | -1.12M▼ 102.0% | -34.7M▼ 3006.4% | -107.8M▼ 210.7% | -9.09M▲ 91.6% | -1.28M▲ 85.9% | -3.63M▲ 0% |
FCF Margin % | 8.39% | 7.65% | 2.5% | 14.06% | -0.24% | -7.53% | -14.44% | -1.14% | -0.16% | -0.44% |
FCF Growth % | 37.99% | -4.76% | -66.8% | 396.81% | -101.95% | -3006.36% | -210.69% | 91.57% | 85.92% | 24.41% |
FCF per Share | 1.97 | 1.83 | 0.61 | 2.95 | -0.06 | -1.73 | -2.94 | -0.24 | -0.03 | -0.09 |
FCF Conversion (FCF/Net Income) | 8.57x | 3.61x | -1.13x | 29.51x | -0.48x | 0.58x | 0.30x | -0.20x | -0.36x | 0.06x |
Interest Paid | 811K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 3.27M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
OFIX Key Ratios
Orthofix Medical Inc. (OFIX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 2.22% | 4.37% | -8.59% | 0.74% | -11.06% | -5.86% | -32.36% | -22.87% | -19.34% | -13.44% |
Return on Invested Capital (ROIC) | 13.93% | 9.38% | -5.16% | -1.66% | -2.23% | -3.42% | -21.07% | -9.9% | -8.58% | -4.29% |
Gross Margin | 78.55% | 78.67% | 78.13% | 74.94% | 75.26% | 73.18% | 65.13% | 68.28% | 67.09% | 69.02% |
Net Margin | 1.43% | 3.05% | -6.19% | 0.62% | -8.26% | -4.29% | -20.28% | -15.76% | -11.21% | -7.27% |
Debt / Equity | - | - | 0.07x | 0.07x | 0.07x | 0.06x | 0.20x | 0.36x | 0.51x | 0.54x |
Interest Coverage | 98.10x | 27.64x | -220.71x | 0.85x | -6.35x | -12.75x | -16.23x | -3.18x | -4.19x | -4.97x |
FCF Conversion | 8.57x | 3.61x | -1.13x | 29.51x | -0.48x | 0.58x | 0.30x | -0.20x | -0.36x | 0.06x |
Revenue Growth | 5.87% | 4.43% | 1.53% | -11.61% | 14.25% | -0.81% | 62.06% | 7.08% | 2.85% | 2.59% |
Related:OFIX Dividend History·OFIX Revenue History·OFIX Price History·OFIX P/E History·OFIX Financial Ratios·OFIX Institutional Holders
OFIX SEC Filings & Documents
Orthofix Medical Inc. (OFIX) SEC filings — annual & quarterly reports (10-K, 10-Q)
OFIX Frequently Asked Questions
Orthofix Medical Inc. (OFIX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Orthofix Medical Inc. (OFIX) reported $825.4M in revenue for fiscal year 2025. This represents a 969% increase from $77.2M in 1996.
Orthofix Medical Inc. (OFIX) grew revenue by 2.9% over the past year. Growth has been modest.
Orthofix Medical Inc. (OFIX) reported a net loss of $60.0M for fiscal year 2025.
Dividend & Returns
Orthofix Medical Inc. (OFIX) has a return on equity (ROE) of -19.3%. Negative ROE indicates the company is unprofitable.
Orthofix Medical Inc. (OFIX) had negative free cash flow of $3.6M in fiscal year 2025, likely due to heavy capital investments.